IgG4-related sclerosing disease is an immune-mediated disease that affects multiple organs at the same time in some people. This can often include an inflamed pancreas, organ swelling, disease in the ...
Obexelimab demonstrated a statistically significant 56% reduction in the risk of IgG4-RD flare compared with placebo. Topline data were announced from a phase 3 trial evaluating obexelimab in ...
To diagnose IgG4-related disease, doctors use a combination of methods, including laboratory tests, clinical evaluation, imaging, and biopsies. Doctors can use imaging and laboratory tests to check ...
A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease ...
Cholangiographic classification of IgG4-SC into 4 types based on stricture location is crucial to differentiate IgG4-SC from other biliary conditions. Characteristic findings on intraductal ...
Please provide your email address to receive an email when new articles are posted on . B-cell depletion with inebilizumab reduced flare risk for pancreatic and/or biliary IgG4-related disease. It ...
WASHINGTON — The B-cell depleting agent inebilizumab (Uplizna) dramatically reduced the risk of flares and increased year-long remission of IgG4-related disease (RD), new research has found. The ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune ...
PDUFA target action date of May 27,2027, following FDA acceptance of obexelimab BLA submission for the treatment of IgG4-RD in August 2026 -- ...
Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "IgG4-Related Disease - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results